Maze Therapeutics, Inc. (MAZE) Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Maze Therapeutics, Inc. NASDAQ:MAZE Healthcare · Biotechnology
Mkt Cap $1.75B
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
Maze Therapeutics will present data on MZE829 and MZE782 at ASN Kidney Week, held October 21-25, 2026 in Denver.
The oral presentation covers previously reported Phase 2 HORIZON data for MZE829 in APOL1-mediated kidney disease, updated with additional details; two posters will cover preclinical research supporting SLC6A19 inhibition (MZE782's mechanism) in chronic kidney disease.
No new data is being announced; the release is a visibility event ahead of the October 24 oral presentation led by Duke's Dr. Opeyemi Olabisi.
• 26d ago AI analysis › Press Release
Maze Therapeutics to Participate in Three Upcoming Investor Conferences
Maze Therapeutics management will participate in fireside chats at three September investor conferences: the Wells Fargo 21st Annual Healthcare Conference (Sept 9), the Citi 2026 Biopharma Back to School Summit (Sept 10), and the H.C. Wainwright 28th Annual Global Investment Conference (Sept 15).
Live webcasts will be available on the company's investor relations site and archived for 60 days after the presentations.
Maze is a clinical-stage biopharma developing small molecule precision medicines for kidney and metabolic diseases, with Phase 2 lead assets MZE829 (APOL1 inhibitor for AMKD) and MZE782 (SLC6A19 inhibitor for PKU and CKD).
• 1mo ago AI analysis › Press Release
Maze Therapeutics Announces Appointments to Its Board of Directors
Maze Therapeutics appointed Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., to its Board of Directors, significantly enhancing the company's clinical and commercial expertise.
Dr. Johnson serves on the board of Johnson & Johnson and is President of Wellesley College, while Dr. Kornowski brings 35 years of biopharmaceutical leadership experience including as CEO of Boston Pharmaceuticals and executive roles at Roche.
CEO Jason Coloma highlighted the company's progress, expecting additional data from MZE829 in late 2026 or early 2027 and initial data from MZE782 in 2027.
• 2mo ago AI analysis › Press Release
Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
Maze Therapeutics reported Q2 2026 financial results with $494.9 million in cash, extending its expected runway into 2029, driven by a $150 million offering closed in April.
The company remains focused on its Phase 2 programs, with the HORIZON trial of MZE829 enrolling and data expected in late 2026 or early 2027, while the Phase 2 CIPheR trial of MZE782 in PKU has initiated with topline data expected in 2027.
Financially, Maze reported a net loss of $44.7 million, or $0.76 per share, for the quarter, compared to a loss of $33.7 million, or $0.77 per share, in the prior year, with $20 million in license revenue recognized in the first half of the year from a milestone with Shionogi.
• 2mo ago AI analysis › Press Release
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
Maze Therapeutics CEO Jason Coloma will present at the Jefferies Global Healthcare Conference on June 3 and the Goldman Sachs Global Healthcare Conference on June 10.
Live webcasts of both presentations will be available on the company's investor relations website and archived for 60 days.
The release serves as a standard calendar notification with no new operational or financial disclosures.
• 5mo ago AI analysis › Press Release
Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
globenewswire.com • 5mo ago Press Release
Maze Therapeutics Announces $150 Million Registered Offering
Maze Therapeutics priced a $150 million registered offering, selling 5.54 million shares of common stock at $23.50 per share.
The offering also includes pre-funded warrants for 850,000 shares at $23.499, with participation from institutional investors including Farallon Capital and T. Rowe Price.
Net proceeds will be used to advance development of MZE829 and MZE782 and to fund operations into 2029.
• 6mo ago AI analysis › 
